213 related articles for article (PubMed ID: 28479492)
1. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study.
O'Connor J; Smith C; Lampe FC; Johnson MA; Chadwick DR; Nelson M; Dunn D; Winston A; Post FA; Sabin C; Phillips AN;
Lancet HIV; 2017 Jul; 4(7):e295-e302. PubMed ID: 28479492
[TBL] [Abstract][Full Text] [Related]
2. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya.
Maina EK; Mureithi H; Adan AA; Muriuki J; Lwembe RM; Bukusi EA
Int J Infect Dis; 2020 Aug; 97():151-158. PubMed ID: 32497804
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after viral load rebound on first-line antiretroviraltreatment in children with HIV in the UK and Ireland: an observational cohort study.
Childs T; Shingadia D; Goodall R; Doerholt K; Lyall H; Duong T; Judd A; Gibb DM; Collins IJ;
Lancet HIV; 2015 Apr; 2(4):e151-8. PubMed ID: 26413561
[TBL] [Abstract][Full Text] [Related]
4. Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.
O'Connor JL; Smith CJ; Lampe FC; Hill T; Gompels M; Hay P; Chadwick D; Fisher M; Ainsworth J; Gilson R; Mackie N; Anderson J; Orkin C; Nelson M; Kegg S; Leen C; Palfreeman A; Post F; Johnson M; Sabin CA; Phillips AN;
AIDS; 2014 Mar; 28(6):919-24. PubMed ID: 24335482
[TBL] [Abstract][Full Text] [Related]
5. Durability of switched therapy after failure of WHO-recommended antiretroviral therapy regimens in a resource-limited setting.
Lumu I; Musaazi J; Castelnuovo B
AIDS; 2022 Nov; 36(13):1791-1800. PubMed ID: 35876663
[TBL] [Abstract][Full Text] [Related]
6. Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland.
Duong T; Judd A; Collins IJ; Doerholt K; Lyall H; Foster C; Butler K; Tookey P; Shingadia D; Menson E; Dunn DT; Gibb DM;
AIDS; 2014 Oct; 28(16):2395-405. PubMed ID: 25389551
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.
Smith CJ; Phillips AN; Dauer B; Johnson MA; Lampe FC; Youle MS; Tyrer M; Staszewski S
HIV Med; 2009 Jan; 10(1):19-27. PubMed ID: 19018880
[TBL] [Abstract][Full Text] [Related]
8. Use of a prescription-based measure of antiretroviral therapy adherence to predict viral rebound in HIV-infected individuals with viral suppression.
Cambiano V; Lampe FC; Rodger AJ; Smith CJ; Geretti AM; Lodwick RK; Holloway J; Johnson M; Phillips AN
HIV Med; 2010 Mar; 11(3):216-24. PubMed ID: 20002781
[TBL] [Abstract][Full Text] [Related]
9. Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy.
May MT; Gompels M; Delpech V; Porter K; Orkin C; Kegg S; Hay P; Johnson M; Palfreeman A; Gilson R; Chadwick D; Martin F; Hill T; Walsh J; Post F; Fisher M; Ainsworth J; Jose S; Leen C; Nelson M; Anderson J; Sabin C;
AIDS; 2014 May; 28(8):1193-202. PubMed ID: 24556869
[TBL] [Abstract][Full Text] [Related]
10. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
Haberer JE; Musinguzi N; Boum Y; Siedner MJ; Mocello AR; Hunt PW; Martin JN; Bangsberg DR
J Acquir Immune Defic Syndr; 2015 Dec; 70(4):386-92. PubMed ID: 26110445
[TBL] [Abstract][Full Text] [Related]
11. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
[TBL] [Abstract][Full Text] [Related]
12. Early age at start of antiretroviral therapy associated with better virologic control after initial suppression in HIV-infected infants.
Shiau S; Strehlau R; Technau KG; Patel F; Arpadi SM; Coovadia A; Abrams EJ; Kuhn L
AIDS; 2017 Jan; 31(3):355-364. PubMed ID: 27828785
[TBL] [Abstract][Full Text] [Related]
13. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.
Raboud J; Blitz S; Walmsley S; Thompson C; Rourke SB; Loutfy MR;
HIV Clin Trials; 2010; 11(6):340-50. PubMed ID: 21239362
[TBL] [Abstract][Full Text] [Related]
14. Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen.
Raffi F; Hanf M; Ferry T; Khatchatourian L; Joly V; Pugliese P; Katlama C; Robineau O; Chirouze C; Jacomet C; Delobel P; Poizot-Martin I; Ravaux I; Duvivier C; Gagneux-Brunon A; Rey D; Reynes J; May T; Bani-Sadr F; Hoen B; Morrier M; Cabie A; Allavena C;
J Antimicrob Chemother; 2017 Dec; 72(12):3425-3434. PubMed ID: 28961719
[TBL] [Abstract][Full Text] [Related]
15. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Teasdale CA; Sogaula N; Yuengling KA; Wang C; Mutiti A; Arpadi S; Nxele M; Pepeta L; Mogashoa M; Rivadeneira ED; Abrams EJ
J Int AIDS Soc; 2018 Aug; 21(8):e25168. PubMed ID: 30094952
[TBL] [Abstract][Full Text] [Related]
16. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
[TBL] [Abstract][Full Text] [Related]
17. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
Phillips AN; Staszewski S; Weber R; Kirk O; Francioli P; Miller V; Vernazza P; Lundgren JD; Ledergerber B; ; ;
JAMA; 2001 Nov; 286(20):2560-7. PubMed ID: 11722270
[TBL] [Abstract][Full Text] [Related]
18. Switch to second-line versus continued first-line antiretroviral therapy for patients with low-level HIV-1 viremia: An open-label randomized controlled trial in Lesotho.
Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Namane T; Mpholo T; Battegay M; Klimkait T; Labhardt ND
PLoS Med; 2020 Sep; 17(9):e1003325. PubMed ID: 32936795
[TBL] [Abstract][Full Text] [Related]
19. Effect of HIV-1 low-level viraemia during antiretroviral therapy on treatment outcomes in WHO-guided South African treatment programmes: a multicentre cohort study.
Hermans LE; Moorhouse M; Carmona S; Grobbee DE; Hofstra LM; Richman DD; Tempelman HA; Venter WDF; Wensing AMJ
Lancet Infect Dis; 2018 Feb; 18(2):188-197. PubMed ID: 29158101
[TBL] [Abstract][Full Text] [Related]
20. A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study.
Jose S; Delpech V; Howarth A; Burns F; Hill T; Porter K; Sabin CA;
Lancet HIV; 2018 Jun; 5(6):e301-e308. PubMed ID: 29893243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]